Transfusion transmitted virus infection in general populations and patients with various liver diseases in south China

Yong Peng Chen, Wei Fang Liang, Lian Zhang, Hai Tang He and Kang Xian Luo

Subject headings: transfusion-transmitted virus; liver disease/etiology; DNA virus; polymerase chain reaction; serodiagnosis; hepatitis viruses

INTRODUCTION

Although several specific detecting methods had been applied to determine the hepatitis virus, there was a lot of cryptogenic hepatitis without any known hepatitis infectious marker[1]. The prevalence of hepatitis G virus (HGV) (also known as GB-C virus) infection has been reported to be 5%-13% in patients with non-A-E hepatitis and cirrhosis, however, there is little evidence suggesting that HGV causes hepatitis in human[2-6]. Although cryptogenic liver diseases are almost certainly related to a variety of etiologies, one or more as-yet-unidentified infectious agents are likely to account for a proportion of these cases.

In December 1997, a novel DNA virus was reported by Nishizawa et al[7] to be associated with elevated aminotransferase levels in patients with post-transfusion hepatitis of unknown etiology (non-A-G hepatitis). This virus was designated transfusion transmitted virus (TTV). Then, Luo et al[8] and Wei et al[9] also detected TTV in the sera of patients from an outbreak of cryptogenic hepatitis in south China. And TTV was also detected in patients with post-transfusion hepatitis in China[10]. In subsequent analyses, TTV is an un-enveloped single-stranded DNA virus for which a sequence of 3800 bases was determined[11]. Evidence of potential hepatotropism of TTV was reported with TTV DNA detected in liver tissue[12]. Histopathological study indicated that the characteristics of liver histology of TTV infected patients are portal inflammation and interlobular bile duct damage[13]. TTV was proposed as the part of causative agent of non-A to G hepatitis. Seroepidemiological studies have shown TTV to have global distribution[12,14,15]. Although the potential association of TTV with cryptogenic hepatitis is intriguing, the pathological and clinical significance of this virus remains to be established.

To assess more thoroughly the etiological role of TTV in the causation of hepatitis, we determined the frequency of TTV infections and their relationship to liver disease in several cohorts of liver diseases and rural population.

PATIENTS AND METHODS

Rural population

Ninety males and 89 females aged from 1 to 73 years were from a natural village with total population of 190 in southeast of Yunnan Province. Among them, 90 persons were of nationality of Han, others of Yi.

Patients with cryptogenic hepatitis

Forty-four patients with cryptogenic hepatitis were admitted in hospital between January 1993 and May 1999, with negative assays for sera marker of hepatitis virus A-E, and also negative assays for anti-nuclear antibody, anti-smooth muscle antibody, EB virus antibody, CMV antibody and anti-mitochon drial antibody. Part of patients were confirmed with liver biopsy suggestive of acute hepatitis.

Patients with HBV related chronic liver diseases

The prevalence of TTV infection was also determined in five cohorts of HBV related chronic liver disease: ① HBsAg asymptomatic carrier (AsC) (n=52); ② Chronic hepatitis B (CHB) (n=46); ③ Chronic hepatic failure (n=40); ④ Active liver cirrhosis (n=39); ⑤ Hepatocyte carcinoma (HCC) (n=21). The diagnosis accorded with diagnostic criterion of viral hepatitis in the Fifth Science Meeting of Infectious Disease and Verminosis (Beijing, 1995)[16].

Nested PCR for the detection of TTV DNA

Evidence for TTV infection was determined by detection of TTV DNA by nested PCR. Nucleic acids were extracted from 100µL serum. TTV DNA was determined by PCR with nested primers described by Okamoto et al[11] that sensitively detect TTV DNA, irrespective of different
genotypes, as well as by Ampli-Taq-DNA Polymerase. In brief, the first round of PCR was performed with RD038 primer (sense: 5’-TGA CTG TGC TAA AGC CTC TA-3’) and NG059 (antisense: 5’-ACA GAC AGA GGA GAA GGC AAC ATG-3’) for 35 cycles (94°C, 45 seconds; 54°C, 45 seconds; 72°C, 60 seconds [additional 7 minutes for the last cycle]), and the second-round PCR was performed with NG061 (sense: 5’-GGC AAC A TG TTA TGG ATA GAC TGG-3’) and NG063 (antisense: 5’-GAC CGT AAA ATG GTA AAG GTT TCA-3’) for 35 cycles with the same conditions. The size of the second-round PCR was 271bp. The amplicons were electrophoresed in 2% agarose gel, stained with ethidium bromide, and photographed under ultraviolet light. All assays were performed in an amplicon-free work area. Positive and negative results were confirmed with repeated assays.

**Direct sequencing of the amplicons**

Direct sequencing of the amplicons was carried out by Cybersyn.

**Statistical analysis**

Prevalence of TTV infection (as measured by TTV DNA detectable in serum by PCR) in rural population and several cohorts of liver disease was determined. Data analysis was carried out using $\chi^2$ test. And the liver function test of chronic hepatitis B was analysed using $t$ test.

**RESULTS**

Sequencing of the amplicons (Figure 1)

![Comparison of nucleic acids sequence between TTV G1b and amplicons and nucleic acids sequence nt1935-2205 of TTV G1b, sera amplicons had a homogeneity of 98.5%, suggesting the presence of TTV DNA in sera.](image)

**Table 1 Prevalence of TTV infection among study cohorts**

| Groups                  | TTV positive rate (n) | TTV negative rate (n) | Total |
|-------------------------|-----------------------|-----------------------|-------|
| Rural population        | 10.61(19)             | 89.39(160)            | 179   |
| Cryptogenic hepatitis$^a$ | 38.63(17)             | 61.37(27)             | 44    |
| HBsAg asymptomatic carrier | 9.62 (5)              | 90.38(47)             | 52    |
| Chronic hepatitis B$^a$     | 15.22 (7)             | 84.78(39)             | 46    |
| HBV related active liver cirrhosis$^c$ | 22.5 (9)            | 77.5(31)              | 40    |
| HBV related hepatic failure$^e$ | 23.08 (9)            | 76.92(30)             | 39    |
| Hepatocyte carcinoma$^l$       | 9.52 (2)              | 90.48(19)             | 21    |
| Total                    | 16.15(68)             | 83.85(353)            | 421   |

$^a\chi^2 = 20.486, P<0.005$ vs rural population; $^b\chi^2 = 0.713, P > 0.25$ vs HBsAg asymptomatic carrier; $^c\chi^2=0.749, P>0.25$ vs chronic hepatitis B; $^d\chi^2=0.853, P>0.25$ vs chronic hepatitis B; $^e\chi^2=0.000, P>0.9$ vs HBsAg asymptomatic carrier.

**Rural population**

Nineteen of 179 (10.61%) unselected healthy peoples were detected TTV DNA positive. The prevalence of TTV infection was indep endent of sex, age and nationality (Table 2).

**Table 2 The prevalence of TTV infection in a natural village in Yunnan Province, regarding of sex, nationality and age**

| Result       | Sex$^d$     | Nationality$^d$ | Age$^d$ | Total |
|--------------|-------------|-----------------|---------|-------|
|              | Male | Female | Total | Han | Yi | Total | <14 | 14-55 | >55 | Total |
| TTV positive | 7    | 12      | 19    | 8   | 11 | 19    | 5   | 13 | 1 | 19 |
| TTV negative | 83   | 77      | 160   | 82  | 78 | 160   | 47  | 102 | 11 | 160 |
| Total        | 90   | 89      | 179   | 90  | 89 | 179   | 52  | 115 | 12 | 179 |

$^d\chi^2=1.335, P>0.2$; $^d\chi^2=0.568, P>0.4$; $^d\chi^2=0.178, P>0.9$. 

**Prevalence of TTV infection (Table 1)**

Table 1 Prevalence of TTV infection among study cohorts

| Groups                  | TTV positive rate (n) | TTV negative rate (n) | Total |
|-------------------------|-----------------------|-----------------------|-------|
| Rural population        | 10.61(19)             | 89.39(160)            | 179   |
| Cryptogenic hepatitis$^a$ | 38.63(17)             | 61.37(27)             | 44    |
| HBsAg asymptomatic carrier | 9.62 (5)              | 90.38(47)             | 52    |
| Chronic hepatitis B$^a$     | 15.22 (7)             | 84.78(39)             | 46    |
| HBV related active liver cirrhosis$^c$ | 22.5 (9)            | 77.5(31)              | 40    |
| HBV related hepatic failure$^e$ | 23.08 (9)            | 76.92(30)             | 39    |
| Hepatocyte carcinoma$^l$       | 9.52 (2)              | 90.48(19)             | 21    |
| Total                    | 16.15(68)             | 83.85(353)            | 421   |

$^a\chi^2 = 20.486, P<0.005$ vs rural population; $^b\chi^2 = 0.713, P > 0.25$ vs HBsAg asymptomatic carrier; $^c\chi^2=0.749, P>0.25$ vs chronic hepatitis B; $^d\chi^2=0.853, P>0.25$ vs chronic hepatitis B; $^e\chi^2=0.000, P>0.9$ vs HBsAg asymptomatic carrier.
**Patients with cryptogenic hepatitis**
The prevalence of TTV infection in patients with cryptogenic hepatitis was 38.63% (17 of 44). Two of the TTV-infected patients with fulminant hepatic failure, while the others with mild hepatitis.

**Patients with HBV related chronic liver disease**
The prevalence of TTV infection of AsC, CHB, ALC, CHF and HCC was 9.62% (5/47), 15.22% (7/47), 22.5% (9/31), 23.08% (9/39) and 9.52% (2/21), respectively. It seemed that the state of illness was related with the co-infection of TTV. However, there was no statistical difference between the prevalences (Table 1).

**Effect on liver function test of TTV co-infection**
While co-infection with TTV, the state of illness did not exacerbate in patients with CHB (Table 3). In patients with active liver cirrhosis and chronic hepatic failure, there were no significant differences in results of laboratory tests in patients with and without TTV DNA (P>0.2) whereas the co-infection of TTV increased the mortality of patients with hepatic failure (P=0.038).

**DISCUSSION**
The recent discovery in Japan by Nishizawa et al[7] of a novel parenterally transmissible, unenveloped, single-stranded DNA virus (TTV) in patients with non-A-G posttransfusion hepatitis had raised some important questions about TTV as a potential cause of liver disease.

Previous study indicated that TTV infection was common in healthy individuals, blood donors, HBsAg AsC, patients on hemodialysis and patients with various liver diseases, however played a minimal role on liver disease[17-26]. Another paper suggested TTV may cause chronic hepatitis in a limited number of patients, but remains dormant most of the time[27]. In our study, we found 10.61% of healthy individuals with normal liver function test were infected with TTV, and the prevalence was independent of sex, age and nationality. The result indicated TTV infection was common in healthy individuals. However, frequency of TTV infection in patients with cryptogenic hepatitis was significantly higher. As evidence of potential hepatotropism of TTV had been reported with TTV-DNA titers shown to be 10 to 100 folds greater in liver tissue than in serum[11,12], TTV would account for part of the reason for patients with cryptogenic hepatitis. As we know that there are many HBsAg AsC, whereas HBV causes many hepatitises. This study suggested that the majority of individuals with TTV could be asymptomatic carriers, with only a small proportion of carriers actually developing hepatitis.

Generally, co-infection of hepatitis virus would lead to exacerbation of hepatitis. While co-infected with hepatitis A and B virus, patients encountered exacerbation of illness, with more severe abnormal results of laboratory tests and higher mortality[28]. In histopathological evaluation, co-infection of hepatitis virus had no significant difference in development of liver cirrhosis[29]. Previous study indicated that superinfection of TTV does not exert deleterious effects on the liver disease induced by HCV. Triple infection, HCV and TTV plus HBV or HGV, did not cause severe liver disease[30]. In current study, prevalence of TTV infection in HBsAg AsC and patients with chronic hepatitis B, HBV related liver cirrhosis and chronic hepatic failure was 9.62%, 15.22%, 22.5% and 23.08% respectively. There was no significant difference among prevalence of TTV infection, suggesting the minor effect on liver disease of co-infection of TTV. The comparison of levels of ALT, AST, total bilirubin, A/G of serum protein and prothrombin time between TT virus-positive and-negative patients did not show any differences, as accorded with another report[30]. However, TTV co-infection increased the mortality of patients with hepatic failure.

Most cases of chronic hepatitis, cirrhosis, and HCC in developed countries are caused by HBV or HCV infections and heavy alcohol intake. A relatively small proportion of liver diseases is of unknown etiology. The recently discovered HGV seems to have no actual role in causing acute or chronic liver disease[31], whereas the role of the more recently discovered TTV is still to be defined. To inquire the relationship between TTV infection and HCC, we investigated the prevalence of TTV infection in HBV infected patients with HCC, and compared with HBsAg AsC. The result indicated similar prevalence in both cohorts (9.52% vs 9.62%, P>0.9), which did not support the hypothesis of an association between TTV infection and HCC, and accorded with previous studies[32,33]. Another report indicated that TTV was not specific for HBV-negative and HCV-negative patients with HCC. For all TTV-positive patients, the TTV genome was not integrated into host hepatocyte DNA[34]. In conclusion, TTV was common in general population and several cohorts of liver disease. Though the majority of individuals with TTV could be asymptomatic carriers, TTV would account for part of cryptogenic hepatitis. As TTV...
co-infection did not affect the state of HBV infection, further study on pathogenic effect on liver disease of TTV infection should be continued.

REFERENCES

1 Kodali VP, Gordon SC, Silverman AL, McCray DG. Cryptogenic liver disease in the United States: further evidence for non A, non B and non-C hepatitis. Am J Gastroenterol. 1994;89:1836-1840

2 De Filippi F, Romeo R, Rumi MG, Donato MF, Del Ninno E, Colombo M. Low prevalence of HGV RNA in Italian patients with non-A-E chronic hepatitis. Hepatology. 1996;24:499A

3 Yamashita K, Oketani M, Oketani K, Yasuda K, Sho Y, Arima T, Maewata F, Hasegawa S, Komorizono Y, Ishimaru K, Inshibashi K, Miyazaki H, Arima T. Cryptogenic severe chronic liver diseases in South Japan. Hepatology. 1996;24:600A

4 Hamid S, Jafri W, Khurshid M, Jarvis L, Shah H, Abbas Z, Sultana T, Siddiqui AA, Khan H, Simmonds P. Hepatitis G virus infection and its relation to liver disease. Hepatology. 1996;24:520A

5 Aikawa T, Sugai Y, Okamoto H. Hepatitis G infection in drug abusers with chronic hepatitis C. N Engl J Med. 1996;334:195-196

6 Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, Shih Aikawa T, Sugai Y, Okamoto H. Hepatitis G infection in drug abusers with chronic hepatitis C. N Engl J Med. 1996;334:195-196

7 Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun. 1997;241:92-97

8 Luo XQ, Zhang L, Wang SS, Nie J, Ge Y, Chen ZY, Yu SY, Liu YY, Yang SC, Liang WF, He HT, Jiao CS. An outbreak of enteric transmitted non A, non E viral hepatitis: primary study of clinical epidemiology and virology. Zhonghua Ganzangbing Zazhi. 1998;6:161-163

9 Wei LP, Liao DX, Liang WF. Investigation of an outbreak of new type of hepatitis in Gaoming of Guangdong Province. Shijie Huaren Xiaohua Zazhi. 1997;7:175-176

10 Yang SS, Wu CH, Chen TH, Huang YW, Huang CS. TT viral infection through blood transfusion: retrospective investigation on patients with a prospective study of post transfusion hepatitis. World J Gastroenterol. 2000;6:70-73

11 Okamoto H, Nishizawa T, Kato N, Ukita M, Ikeda H, Iizuka T. Hepatitis G virus infection: histopathological evaluation. Zhonghua Ganzangbing Zazhi. 1997;9:96-98

12 Xu DJ, Lang ZW, Wang GY, Yan HP, Xu RP, Li DF, Zhou YS, Wang HT. Detec tion of TTV DNA in liver tissue of patients with non-A-G hepatitis. Zhonghua Ganzangbing Zazhi. 1997;9:1029-1030

13 Ge Y, Ren X, Li DZ, Hu TH, Yang Q. Liver histological characteristics of patients with TTV infection during an epidemic of TTV infection in Wuhan. Shijie Huaren Xiaohua Zazhi. 1999;7:497-498

14 Naumov NV, Petrova EP, Thomas MG, Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet. 1998;352:195-197

15 Charlton M, Adjie P, Poterucha J, Zein N, Moore B, Therneau T, Krom R, Wiesner R. TT virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology. 1998;28:839-842

16 Protocol of prevention and treatment for viral hepatitis. Zhonghua Chuanranbing Zazhi. 1995;13:241-246

17 Chen TY, Zhang SL. Prognosis in TTV studies. Shijie Huaren Xiaohua Zazhi. 1999;7:420-421

18 Fu EQ, Bai XF, Pan L, Li GY, Yang WS, Tang YM, Wang PZ, Sun JF. Investigation of TT virus infection in groups of different people in Xi’an. Shijie Huaren Xiaohua Zazhi. 1999;7:967-969

19 Yu JG, Han JJ, Xiao DM, Yin YM, Shang QH, Zhou XM, Du QL, Zhang GS. Investigation of TTV infection and partial sequence analysis of TTV DNA in Sha ndong. Shijie Huaren Xiaohua Zazhi. 2000;8:352-354

20 Yang J, Wang YC, Zhang HY, Li HM. TTV infection in various kind of populations in China. Shijie Huaren Xiaohua Zazhi. 1999;7:497-498

21 Chen XJ, Peng XM, Gao ZL, Lu JX, Yao JL. The significance of TTV infection in normal population and patients liver diseases. Shijie Huaren Xiaohua Zazhi. 1999;7:5-7

22 Huang CH, Zhou YS, Chen RG, Xie CY, Wang HT. The prevalence of transfusion transmitted virus infection in blood donors. World J Gastroenterol. 2000;6:268-270

23 Kao JH, Chen W, Hsiang SC, Chen PJ, Lai MY, Chen DS. Prevalence and implication of TT virus infection: minimal role in patients with non-A-E hepatitis in Taiwan. J Med Virol. 1999;59:307-312

24 Forns X, Hegerich P, Darnell A, Emerson SU, Purcell RH, Bukh J. High prevalence of TTV virus (TTV) infection in patients on maintenance hemodialysis: frequent mixed infections with different genotypes and lack of evidence of associated liver disease. J Med Virol. 1999;59:313-317

25 Abe K, Inami T, Anaso K, Miyoshi C, Masaki N, Hayashi S, Ishikawa KI, Takebe Y, Win KM, El Zayadi AR, Han HK, Zhang DY. TT virus infection is widespread in the general populations from different geographic regions. J Clin Microbiol. 1999;37:2703-2705

26 Hsieh SY, Wu YH, Ho YP, Tsao KC, Yeh LF. High prevalence of TT virus infection in healthy children and adults and in patients with liver disease in Taiwan. J Clin Microbiol. 1999;37:1829-1831

27 Ikekuchi T, Okuda K, Yokosuka O, Kanda T, Kobayashi S, Murata M, Hayashi H, Yokozeki K, Ohtake Y, Kashima T, Irie Y. Superinfection of TT virus and hepatitis C virus among chronic haemodialysis patients. J Gastroenterol Hepatol. 1999;14:796-800

28 Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases. Am J Gastroenterol. 1995;90:201-205

29 Colombari R, Dhillon AP, Pizzolato E, Tomezzi CA, Angelini GP, Capra F, Tomba A, Scheuer PJ. Chronic hepatitis with multiple virus infection: histopathological evaluation. Histopathology. 1993;22:319-325

30 Hayashi K, Fukuda Y, Hayakawa T, Kumada T, Nakano S. TT virus (TTV) infection in patients with acute hepatitis. Nippon Rinsho. 1999;57:1322-1325

31 Theodore D, Lennom SM, GB virus C, hepatitis G virus, or human orphan flavivirus? Hepatology. 1997;25:1285-1286

32 Tagger A, Donato F, Ribero ML, Binelli G, Gelatti U, Portera G, Albertini A, Fasola M, Chiesa R, Nardi G, Study BH. A case control study on a novel DNA virus (TTV) infection and hepatocellular carcinoma. Hepatology. 1999;30:294-299

33 Shimizu T, Moriyama M, Matsumura H, Arakawa Y. TT virus infection in patients with hepatocellular carcinoma associated with non A to G hepatitis: histopathological study. Nippon Rinsho. 1999;57:1381-1386

34 Yamamoto T, Kajino K, Ogawa M, Gotoh I, Matsuoka S, Suzuki K, Moriyama M, Okubo H, Kudo M, Arakawa Y, Hino O. Hepatocellular carcinomas infected with the novel TT DNA virus lack viral integration. Biochem Biophys Res Commun. 1998;251:339-343

Edited by Ma JY